Breaking: Experimental Coronavirus Vaccine Data ‘Encouraging,’ Scientists Say

An experimental coronavirus vaccine triggered an immune response against COVID-19 in study participants, and it has only minor side effects, according to new data published in the medical journal The Lancet.

The vaccine, called AZD1222 for now, is being developed by Oxford University and AstraZeneca. It uses a different, harmless virus to deliver biological instructions for how to fight off the coronavirus.

According to a phase one/phase two study of more than 1,000 patients, the vaccine triggered two immune responses: an increase in antibodies and a T-cell response.

This, scientists said, is a good sign.

“So far, everything we’ve seen has been encouraging,” said Naor Bar-Zeev, deputy director of the International Vaccine Access Center at Johns Hopkins University. He was not involved with this study. And he said there have not been any severe reactions.

Reported reactions were more common among patients who received the coronavirus vaccine than those who received the control, which was a meningitis vaccine. They included muscle ache, chills and feeling feverish. But acetaminophen relieved those symptoms, the researchers wrote.

Study enrollment took place between April 23 and May 21, and included 1,077 participants from 18 to 55 years old who had not previously tested positive for the coronavirus. Although the gender breakdown was fairly even, study participants were mostly white. The study was single-blind, meaning patients did not know whether they received the coronavirus vaccine or the control.

Professor Adrian Hill, one of the study authors, said that the two-pronged immune response is ideal. The antibodies prevent healthy cells from becoming infected, and the T-cells work to kill cells that have already become infected.

“Having both of these after vaccination — sometimes after a single dose, but much better after a second dose — is pretty encouraging,” said Hill, who directs the Jenner Institute at the University of Oxford.

“Nobody can say for certain what you need to get protection in this disease because it’s never been done before,” he said. He added that the magnitude of the immune response was what they hoped for and was at the level “that seems to work in fundamental studies in animals and certainly right up there compared to using this sort of vaccine technology before.”

The researchers said it’s encouraging that they didn’t find any serious adverse reactions, but they cautioned more research is needed to understand rarer reactions to the vaccine, which may not appear in 1,000 people but could turn up once the vaccine is given to millions of Americans, Bar-Zeev said.

Hill agreed there’s still plenty that can go wrong, which is why he and his colleagues are rooting for other vaccine candidates to have positive study results as well.

Although the study was done well, it’s important to remember it’s a “progress report,” said Robert Gallo, co-founder and director of the Institute of Human Virology at the University of Maryland School of Medicine. It’s too soon to declare victory.

“People are looking for antibodies that, in the lab, will block infection in a culture system, called ‘neutralizing antibodies.’ And that sounds very good,” said Gallo, who is also the co-founder and international scientific adviser of the Global Virus Network. “Sometimes, that correlates with protection in vaccines. … And sometimes it does not. And many times it does not.”

The Oxford-AstraZeneca vaccine works by…

Continue reading at NPR.COM

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *


Newsletter

 Sign up now to receive our Daily Newsletters, straight to your inbox.